Benefits of Implementing Bispecific Therapies in the Community

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,John Allan, MD

Panelists discuss the benefits of implementing bispecific therapy programs in the community setting as well as factors influencing the decision to administer these agents at an academic center vs a community setting.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP: 5.ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP: 6.MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP: 7.Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP: 8.Key Strategies for Preventing CRS and ICANS

EP: 9.Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP: 10.Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP: 11.Successful Implementation of Bispecific Therapies: Expert Recommendations

Now Viewing

EP: 12.Benefits of Implementing Bispecific Therapies in the Community

Video content above is prompted by the following:

What are the benefits of implementing bispecific therapy programs in the community setting? (Dr Graff)
What factors might influence the decision to administer these agents at an academic center instead of a community setting? (Dr Allan)